Interferon-beta 1a and SARS coronavirus replication.
A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon-beta 1a potently inhibits SARS coronavirus replication in vitro.
Hensley
Lisa E
LE
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA.
Fritz
Lisa E
LE
Jahrling
Peter B
PB
Karp
Christopher L
CL
Huggins
John W
JW
Geisbert
Thomas W
TW
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002522:Chlorocebus aethiops; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000494:pharmacology; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000494:pharmacology*; D011994:Recombinant Proteins; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects* / Q000502:physiology*; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D014709:Vero Cells; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D016899:Interferon-beta; D000068556:Interferon beta-1a